Helen Sabzevari, Ph.D., President and CEO of Precigen, shares insights on innovative adenovirus-based therapies. She discusses the promising use of gorilla adenovectors, which enhance the delivery of large genetic payloads for effective gene therapies. Sabzevari reveals exciting results from Precigen's recent BLA submission, with over 50% of patients achieving Complete Response in pivotal studies. She also highlights the company's groundbreaking work in treating recurrent respiratory papillomatosis and the potential for broad applications in immuno-oncology and beyond.

Herman Chan discusses FDIC's plan for refilling deposit insurance funds. Dr. Helen Sabzevari talks about drug development for weight loss, cancer, and health treatments. Brian Stelter discusses his book 'Network of Lies.' Laura Martin shares her bearish outlook on Meta stock, Apple, and Disney.